These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8369370)
1. Optimum experimental designs for properties of a compartmental model. Atkinson AC; Chaloner K; Herzberg AM; Juritz J Biometrics; 1993 Jun; 49(2):325-37. PubMed ID: 8369370 [TBL] [Abstract][Full Text] [Related]
2. [Value of the theory of the optimal sampling scheme for bioequivalence studies]. Tod M; Petitjean O; Nicolas P Therapie; 1993; 48(1):7-13. PubMed ID: 8356559 [TBL] [Abstract][Full Text] [Related]
3. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models. Daimon T; Goto M Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822 [TBL] [Abstract][Full Text] [Related]
4. Improved designs for dose escalation studies using pharmacokinetic measurements. Piantadosi S; Liu G Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785 [TBL] [Abstract][Full Text] [Related]
6. Can bioavailability of low-variance drugs be estimated with an unpaired, sparse sampling design? Wright PM; Fisher DM Clin Pharmacol Ther; 1998 Apr; 63(4):437-43. PubMed ID: 9585798 [TBL] [Abstract][Full Text] [Related]
7. Robust and efficient design of experiments for the Monod model. Dette H; Melas VB; Pepelyshev A; Strigul N J Theor Biol; 2005 Jun; 234(4):537-50. PubMed ID: 15808874 [TBL] [Abstract][Full Text] [Related]
8. Comparison of robust criteria for D-optimal designs. Foo LK; McGree J; Eccleston J; Duffull S J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies. Duffull SB; Graham G; Mengersen K; Eccleston J J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524 [TBL] [Abstract][Full Text] [Related]
10. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods. Jordan P; Brunschwig H; Luedin E Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371 [TBL] [Abstract][Full Text] [Related]
12. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study. Liao JJ Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699 [TBL] [Abstract][Full Text] [Related]
13. Sample size calculation for the Power Model for dose proportionality studies. Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics: statistical moment calculations. Gouyette A Arzneimittelforschung; 1983; 33(1):173-6. PubMed ID: 6681972 [TBL] [Abstract][Full Text] [Related]
15. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. Konsil J; Dechasathian S; Mason DH; Stevens RE J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869 [TBL] [Abstract][Full Text] [Related]
18. A short introduction to pharmacokinetics. Urso R; Blardi P; Giorgi G Eur Rev Med Pharmacol Sci; 2002; 6(2-3):33-44. PubMed ID: 12708608 [TBL] [Abstract][Full Text] [Related]
19. Probabilistic methods for addressing uncertainty and variability in biological models: application to a toxicokinetic model. Banks HT; Potter LK Math Biosci; 2004 Dec; 192(2):193-225. PubMed ID: 15627493 [TBL] [Abstract][Full Text] [Related]